<?xml version="1.0" encoding="UTF-8"?>
<results title="zoonosis">
 <result pre="syndrome coronavirus 2 SARS-CoV-2) and the disease that it causes" exact="coronavirus disease 2019" post="(COVID-19) have changed the world we know. Yet, the"/>
 <result pre="mechanisms contribute to the deteriorating effects on the organism during" exact="SARS-CoV-2 infection." post="Both humoral and cellular immune responses are involved in"/>
 <result pre="Anti-SARS-CoV-2 antibodies COVID-19 treatment Plasma therapy Core Tip: Since the" exact="coronavirus disease 2019" post="(COVID-19) results from the interaction between the severe acute"/>
 <result pre="factors and to control and regulate the pathophysiological processes during" exact="SARS-CoV-2 infection." post="Moreover, immune-mediated and humoral immune responses, immune memory, the"/>
 <result pre="reported human coronavirus members. These are HCoV-OC43, HCoV229E, SARS-CoV, HCoV-HKU1," exact="Middle East respiratory syndrome" post="corona virus (MERS-CoV), and HCoVNL63[3,4]. Over the last twenty"/>
 <result pre="into the evolution and host distribution of these SARS-CoV-2-related viruses[8,9]." exact="Coronavirus disease 2019" post="(COVID-19) is the illness associated with SARS-CoV-2 infection. The"/>
 <result pre="viruses[8,9]. Coronavirus disease 2019 (COVID-19) is the illness associated with" exact="SARS-CoV-2 infection." post="The clinical syndrome is characterized by variable symptoms, ranging"/>
 <result pre="shedding are not shown. ARDS: Acute respiratory distress syndrome; SARS-CoV-2:" exact="Severe acute respiratory syndrome" post="coronavirus 2; ACE2: Angiotensin-converting enzyme 2. SARS-CoV and SARS-CoV-2"/>
 <result pre="profile[43,45]. Some of the immunological responses that are accompanying the" exact="SARS-CoV-2 infection" post="are presented in Figure 1. CLINICAL MANIFESTATIONS OF COVIDâ€&quot;19"/>
 <result pre="of COVID-19 and the disease severity. A common complication of" exact="SARS-CoV-2 infection" post="is the development of ARDS. The latter is assumed"/>
 <result pre="aspect of the unclear immune response and immune memory regarding" exact="SARS-CoV-2 infection" post="is the desire of the world to have an"/>
 <result pre="promising targets to use in the creation of vaccines against" exact="SARS-CoV-2 infection" post="and therapy, but additional laboratory and clinical evidence are"/>
 <result pre="to the immune responses. If we accept the division of" exact="SARS-CoV-2 infection" post="into three stages, at the beginning of the infection"/>
 <result pre="3 Treatment modalities related to the immunological mechanisms observed during" exact="coronavirus disease 2019." post="ACE2: Angiotensin-converting enzyme 2; ARDS: Acute respiratory distress syndrome;"/>
 <result pre="syndrome; MHC: Major histocompatibility complex; MSCs: Mesenchymal stromal/stem cells; SARS-CoV-2:" exact="Severe acute respiratory syndrome" post="coronavirus 2. Antibody and plasma therapy are the next"/>
 <result pre="favorable results for use in patients with acute and severe" exact="SARS-CoV-2 infection." post="In addition, the development of a recombinant human monoclonal"/>
 <result pre="MSCs properties because T cells do not activate well in" exact="SARS-CoV-2 infection." post="The use of a â€œlicensing approachâ€� is being considered:"/>
 <result pre="would be of great significance for the detailed understanding of" exact="SARS-CoV-2 infection." post="Conflict-of-interest statement: The authors have no conflicts of interest."/>
 <result pre="(Manis javanica)Viruses201911 10ChenNZhouMDongXQuJGongFHanYQiuYWangJLiuYWeiYXiaJYuTZhangXZhangLEpidemiological and clinical characteristics of 99 cases of" exact="2019 novel coronavirus pneumonia" post="in Wuhan, China: a descriptive studyLancet202039550751332007143 11LiuKFangYYDengYLiuWWangMFMaJPXiaoWWangYNZhongMHLiCHLiGCLiuHGClinical characteristics of"/>
 <result pre="ColdJAMA2020 17WoelfelRCormanVMGuggemosWSeilmaierMZangeSMuellerMANiemeyerDVollmarPRotheCHoelscherMBleickerTBrueninkSSchneiderJEhmannRZwirglmaierMDrostenCWendtnerCClinical presentation and virological assessment of hospitalized cases of" exact="coronavirus disease 2019" post="in a travel-associated transmission clusterMedRxiv2020 18BaiYYaoLWeiTTianFJinDYChenLWangMPresumed Asymptomatic Carrier Transmission"/>
 <result pre="Host Microbe20161918119326867177 35ChannappanavarRFehrARZhengJWohlford-LenaneCAbrahanteJEMackMSompallaeRMcCrayPBJrMeyerholzDKPerlmanSIFN-I response timing relative to virus replication determines" exact="MERS coronavirus" post="infection outcomesJ Clin Invest20191293625363931355779 36de WitEvan DoremalenNFalzaranoDMunsterVJSARS and MERS:"/>
</results>
